Lilly
Biotech

Lilly's $2.3B Ajax drug works ‘right out of the gate’

The early data showed the novel JAK2 inhibitor “started working right out of the gate, with a good safety profile,” Lilly’s Jake Van Naarden said.
Angus Liu Jun 13, 2026 11:15am
Bull market

Biotech IPOs here to stay after another record-breaking listing

Jun 12, 2026 11:00am
NVS

Novartis dystrophy data tee up regulatory talks on Avidity drug

Jun 12, 2026 4:30am
London

Fierce Biotech heading to UK amid London Life Sciences Week

Jun 11, 2026 4:57am
A blue-toned graphic showing assorted pills and capsules scattered across a close-up of a 100 bill with Benjamin Franklin

Ipsen R&D chief on pipeline discipline and 2026 milestones

Jun 12, 2026 9:57am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Perrigo CEO ousted over ‘personal conduct’—Chutes & Ladders

Jun 12, 2026 8:30am
More News
Fierce Pharma

Inside Astellas CEO's plan to counter Xtandi's patent cliff

Jun 11, 2026 6:00pm

3 Genentech VPs among those dismissed in latest layoff round

Jun 11, 2026 2:30pm
Fierce Healthcare

HHS ramps up AI use cases, with most in pre-deployment: BPC

Jun 11, 2026 2:00pm
Fierce Pharma

Novo reports data breach, urges patients to 'remain vigilant'

Jun 11, 2026 1:18pm